Barnathan, E.S.

patient level mortality study trial abciximab syndrome troponin 30 days heart death treatment revascularisation baseline infarction group quartile elevation outcome 1- year mortality angina gusto troponin t marker result artery circulation effect antibody model platelet /iiia disease country nt-probnp gusto iv-acs heparin table c-reactive protein factor hospital artery disease event inhibitor investigator difference 1 year depression value characteristic variation iv-ac placebo association 30- analysis protein infusion revascularization thrombocytopenia therapy intervention st-segment signi c-reactive follow-up coagulation 0.001 heparin-induced thrombocytopenia figure analyses glycoprotein strategy randomized 48 hours flammation randomized treatment groups anti-pf 4/heparin antibodies gusto-iv weight